ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Clinical trial NCT05609994 · RECRUITING

Trial details

NCT number: NCT05609994
Sponsor: Katy Peters, MD, PhD
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Low Grade Glioma of Brain

Start date: 2025-07-15
Primary completion: 2027-08-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.